Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vascular Solutions, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Postpones proposed $40 mil. initial public offering, citing "turbulent" market conditions. A re-evaluation is planned in January. The Minneapolis maker of the Duett vascular sealing device filed a preliminary prospectus for the offering in July with the Securities and Exchange Commission (1"The Gray Sheet" Aug. 9, p. 14)

You may also be interested in...

Vascular Solutions Preparing For Duett Vascular Sealing Launch, Going Public

Vascular Solutions says it will allocate roughly $12 mil. of its upcoming $40 mil. initial public offering to establish a direct U.S. sales force over the next year to market the Duett vascular sealing device, which currently awaits FDA approval.

WHO No-Go Not A Swan Song For Remdesivir In India?

The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts